Ovarian cancer data help Mersana raise $152M to top off $9B month of follow-ons

Catalyzed by interim data unveiled Wednesday from a Phase I trial of its lead product, Mersana raised $152 million late Thursday to advance its clinical and preclinical antibody-drug conjugates.

Mersana Therapeutics Inc. (NASDAQ:MRSN), which also presented the data Friday at the virtual American Society of Clinical Oncology meeting, sold 8 million shares at $19 in a bumped-up offering. The price is a 4% premium to the company’s Wednesday close of $18.19; it proposed Thursday morning to sell 5 million shares...